Johnson & Johnson (NYSE:JNJ) Upgraded to Buy at Vetr

Vetr upgraded shares of Johnson & Johnson (NYSE:JNJ) from a hold rating to a buy rating in a report issued on Wednesday, December 20th. The firm currently has $147.14 price objective on the stock.

JNJ has been the subject of a number of other reports. Citigroup increased their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a buy rating in a research report on Monday, October 23rd. Zacks Investment Research cut shares of Johnson & Johnson from a buy rating to a hold rating in a research report on Tuesday, December 12th. BMO Capital Markets raised their price objective on shares of Johnson & Johnson to $161.00 and gave the stock an outperform rating in a research report on Tuesday, December 12th. Leerink Swann reaffirmed an outperform rating and set a $165.00 target price (up previously from $150.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Finally, Royal Bank of Canada increased their target price on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an outperform rating in a research note on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson presently has a consensus rating of Hold and an average target price of $145.94.

Johnson & Johnson (NYSE:JNJ) opened at $145.76 on Wednesday. The stock has a market cap of $391,590.00, a P/E ratio of 25.31, a price-to-earnings-growth ratio of 2.67 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 52 week low of $110.76 and a 52 week high of $146.42.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the prior year, the firm earned $1.68 EPS. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. equities research analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.31%. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

Institutional investors have recently added to or reduced their stakes in the stock. Harding Loevner LP acquired a new stake in Johnson & Johnson during the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. increased its position in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares in the last quarter. Mountain Capital Investment Advisors Inc acquired a new stake in Johnson & Johnson during the 2nd quarter worth approximately $124,000. Finally, Shine Investment Advisory Services Inc. acquired a new stake in Johnson & Johnson during the 2nd quarter worth approximately $177,000. Institutional investors and hedge funds own 65.70% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://ledgergazette.com/2018/01/13/johnson-johnson-jnj-upgraded-to-buy-by-vetr.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply